Gastric Cancer: 胃癌出血患者接受姑息放疗后的治疗效果分析

2021-11-16 MedSci原创 MedSci原创

胃是人体重要的消化器官,一旦患病会对人体健康造成很大的影响,目前胃癌是全球第二大癌症死因,其中一半的胃癌发生在中国

    胃癌是全球第五大常见癌症和第四大癌症相关死亡原因,由于胃癌在亚洲很普遍,亚洲国家有大量胃癌患者在晚期阶段被诊断出来。尽管全身治疗有所改善,但晚期胃癌患者的生存率仍然有限。超过一半的不可切除胃癌患者可能会出现肿瘤相关并发症,需要干预。姑息性放疗手术是一种有效的治疗方法,但对于老年患者和体能状况不佳的患者来说往往比较困难。因此,本项研究旨在评估姑息性放疗的有效性,并探究了生物有效剂量 (BED) 是否与胃癌患者的生存、治疗反应或再出血是否相关。

 

      研究方案主要是将符合输血标准的胃癌晚期患者(血红蛋白水平< 8.0 g/dL)纳入本项研究。主要观察终点是4周时的意向治疗 (ITT) 出血反应率。治疗响应需要满足以下所有标准:(i) 血红蛋白水平≥8.0 g/dL;(ii) 在入组和采血之间的任何时间连续7天没有输血;(iii) 未对出血性胃癌进行挽救性治疗(手术、内镜治疗、经导管栓塞或再放疗)。再出血被定义为需要输血或抢救治疗。

 

      本项研究总共招募了来自15个医疗机构的55名患者。在第 2、4 和 8 周时,ITT 响应率分别为 47%、53% 和 49%。在第 2、4 和 8 周时,符合方案的响应率分别为 56%、78% 和 90%。治疗反应和BED都不能预测晚期胃癌患者的总生存期。多变量Fine-Gray 模型显示 BED 不是反应的重要预测因子。单变量 Cox 模型显示 BED 与再出血没有显着相关性。

 

      研究最后作者说道本项研究证明了接受相对低辐射剂量治疗的患者的对姑息性治疗反应率较高。姑息性放疗在改善贫血方面可能非常有效,但具有轻微的毒性。出血性胃癌的姑息干预策略应考虑到这些患者的生存期有限。

 

 

原始出处:

Tetsuo Saito. Et al. Treatment response after palliative radiotherapy for bleeding gastric cancer: a multicenter prospective observational study (JROSG 17-3). Gastric Cancer.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1712966, encodeId=dde41e1296629, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Apr 02 02:42:29 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893721, encodeId=703e1893e213a, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jul 17 10:42:29 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894258, encodeId=e985189425891, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat May 21 10:42:29 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073470, encodeId=835d20e3470b6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Oct 20 10:42:29 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911017, encodeId=46dc191101eb9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 30 22:42:29 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626675, encodeId=794616266e57d, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Thu Nov 18 11:42:29 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1712966, encodeId=dde41e1296629, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Apr 02 02:42:29 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893721, encodeId=703e1893e213a, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jul 17 10:42:29 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894258, encodeId=e985189425891, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat May 21 10:42:29 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073470, encodeId=835d20e3470b6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Oct 20 10:42:29 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911017, encodeId=46dc191101eb9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 30 22:42:29 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626675, encodeId=794616266e57d, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Thu Nov 18 11:42:29 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-07-17 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1712966, encodeId=dde41e1296629, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Apr 02 02:42:29 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893721, encodeId=703e1893e213a, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jul 17 10:42:29 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894258, encodeId=e985189425891, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat May 21 10:42:29 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073470, encodeId=835d20e3470b6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Oct 20 10:42:29 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911017, encodeId=46dc191101eb9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 30 22:42:29 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626675, encodeId=794616266e57d, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Thu Nov 18 11:42:29 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1712966, encodeId=dde41e1296629, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Apr 02 02:42:29 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893721, encodeId=703e1893e213a, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jul 17 10:42:29 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894258, encodeId=e985189425891, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat May 21 10:42:29 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073470, encodeId=835d20e3470b6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Oct 20 10:42:29 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911017, encodeId=46dc191101eb9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 30 22:42:29 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626675, encodeId=794616266e57d, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Thu Nov 18 11:42:29 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-10-20 许安
  5. [GetPortalCommentsPageByObjectIdResponse(id=1712966, encodeId=dde41e1296629, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Apr 02 02:42:29 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893721, encodeId=703e1893e213a, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jul 17 10:42:29 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894258, encodeId=e985189425891, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat May 21 10:42:29 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073470, encodeId=835d20e3470b6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Oct 20 10:42:29 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911017, encodeId=46dc191101eb9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 30 22:42:29 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626675, encodeId=794616266e57d, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Thu Nov 18 11:42:29 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1712966, encodeId=dde41e1296629, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Apr 02 02:42:29 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893721, encodeId=703e1893e213a, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jul 17 10:42:29 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894258, encodeId=e985189425891, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sat May 21 10:42:29 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073470, encodeId=835d20e3470b6, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Oct 20 10:42:29 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911017, encodeId=46dc191101eb9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon May 30 22:42:29 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626675, encodeId=794616266e57d, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Thu Nov 18 11:42:29 CST 2021, time=2021-11-18, status=1, ipAttribution=)]

相关资讯

BMJ:姑息治疗对终末期非肿瘤患者的意义

姑息治疗对改善晚期慢性器官衰竭患者生活质量有益,但会增加痴呆晚期患者医疗负担

Prostate Cancer P D:接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究

在晚期癌症患者中使用住院病人姑息治疗(IPC)是较为完善的指南建议。之前的分析阐释了泌尿生殖系(GU)癌症患者在4个检查的原发性癌症(肺癌、乳腺癌、结直肠癌和GU)患者中受益于IPC的比例为排序第3。基于这些结果,研究人员在接受重症监护治疗(CCT)的转移前列腺癌(mPCa)患者中调查了IPC使用的当前趋势和预测因子。研究发现,在接受CCT治疗的4168名mPCa患者中,449名(11.3%)进行

2019 EAPC立场声明:心衰患者的姑息治疗

2019年8月,欧洲姑息治疗学会(EAPC)发布了心衰患者的姑息治疗立场声明。现代姑息治疗适用于所有患有不治之症的患者,并不仅限于癌症。姑息治疗适用于疾病进展的每个阶段,本文主要针对心衰患者的姑息治疗提供声明建议。

Chest:晚期肺癌患者临终时姑息治疗与医疗资源使用和治疗质量的关联

姑息治疗(尤其是在门诊)能减少晚期肺癌患者临终时的医疗资源使用,并改善治疗质量。

2019 欧洲初级医疗论坛意见书:初级医疗保健中的姑息治疗

本文的主要目的是为初级医疗保健工作人员,政策制定者和决策人员针对欧洲初级医疗保健中的姑息治疗提供协助。